title: Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
abstract: Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the outcome of patients with Philadelphia-negative MPN or MDS/MPN in blast phase who received an allo-SCT. Sixty patients were included in this retrospective study. AML was secondary to an MPN in 43 cases, whereas AML evolved from an MDS/MPN in 17 cases. Patients received allo-SCT in CR or advanced disease in 26 cases and 34 cases, respectively. With a median follow-up of 31 months (range, 25-44), OS and leukemia-free survival (LFS) were, respectively, 18% and 9% at 3 years. CR at transplant was associated with an improved LFS in univariate and multivariate analysis. The 3-year LFS was 18% for patients undergoing allo-SCT in CR versus 3% in advanced disease (P=0.008). Absence of thrombosis and an intermediate or favorable AML karyotype were associated with an improved outcome for patients who received allo-SCT in CR. New strategies are needed to improve the outcome of patients with MPN-MDS/MPN in blast phase.
authors.affiliation: Hématologie Clinique, CHU Rennes, Hôpital Pontchaillou, Rennes, France.
authors.forename: X
authors.initials: X
authors.lastname: Cahu
authors.affiliation: Hématologie Clinique, CHU Nantes, Hôtel Dieu, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Chevallier
authors.affiliation: Hématologie Clinique, CHU Angers, Angers, France.
authors.forename: A
authors.initials: A
authors.lastname: Clavert
authors.affiliation: Hématologie Adulte, Hôpital Necker, AP-HP, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Suarez
authors.affiliation: Hématologie Clinique, Hospices Civils de Lyon, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.affiliation: Hématologie Adulte, Hopital Saint-Eloi, Montpellier, France.
authors.forename: L
authors.initials: L
authors.lastname: Vincent
authors.affiliation: Service d' Hématologie, Hôpital Haut Levêque, Pessac, France.
authors.forename: S
authors.initials: S
authors.lastname: Vigouroux
authors.affiliation: Service de Greffe de moelle, Institut Paoli Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.affiliation: Clinique Universitaire d'Hématologie, CHU Grenoble, France.
authors.forename: C
authors.initials: C
authors.lastname: Mariette
authors.affiliation: Hématologie Clinique, Hôpital de Hautepierre, CHU Strasbourg, France.
authors.forename: K
authors.initials: K
authors.lastname: Bilger
authors.affiliation: Service d'Hématologie-greffe, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Robin
authors.affiliation: Hématologie Clinique, Hôpital Claude Huriez, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.affiliation: Service d'Hématologie-greffe, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Peffault de Latour
authors.affiliation: Hématologie Clinique, Hôpital Saint Antoine, AP-HP, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts; D001752:Blast Crisis / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D005602:France; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D054437:Myelodysplastic-Myeloproliferative Diseases / Q000473:pathology* / Q000628:therapy*; D012189:Retrospective Studies